The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...
Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...
A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...
GLP-1 receptor agonists (GLP-1Ras) significantly outperformed Aspirin (acetylsalicylic acid) in reducing the risk of colorectal cancer, regardless of a patient’s weight or diabetes status, according ...
Network map of 29 authors with frequency greater than five. Nodes represent authors, and the larger the node, the higher the number of papers. The lines represent collaborations with other authors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback